✦ LIBER ✦

4. Implications for the Therapeutic Process of a Clinical Team Focus on Family Interaction

✍ Scribed by CHESTER R. DIETZ

Book ID: 114947934
Publisher: American Psychological Association
Year: 1962
Tongue: English
Weight: 251 KB
Volume: 32
Category: Article
ISSN: 0002-9432
DOI: 10.1111/j.1939-0025.1962.tb00288.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Beneficial factors in family discussion

Beneficial factors in family discussion groups of a psychiatric day clinic: perceptions by the therapeutic team and the families of the therapeutic process

✍ Gilbert M. Lemmens; Saskia Wauters; Magda Heireman; Ivan Eisler; Germain Lietaer 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Focus on Economic Sociology A Principal-

Focus on Economic Sociology A Principal-Agent Analysis of the Family: Implications for the Welfare State

✍ Lauchlan T. Munro 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

A current appraisal of drug interactions

A current appraisal of drug interactions of significance in clinical practice: focus on antifungal therapeutic agents used in the treatment of superficial mycoses

✍ James Q. Del Rosso 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Cost-Efficacy Analysis of 3-Hydroxy-3-Me

Cost-Efficacy Analysis of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection

✍ Dr. Pang H. Chong; Dwight Varner 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

A comparison of the effects of lamotrigi

A comparison of the effects of lamotrigine on neuroma-induced action potential firing and normal behaviour in rat: implications for establishing a pre-clinical ‘therapeutic index’

✍ Paul Butler; Jennifer C. Gardiner; James P. Loftus; Eric Karran; Sarah J. Roffey 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4